Clinical Trial Update: A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum [Phase 1]

View source ↗

Summary

A Phase 1 HIV vaccine trial evaluating CH505M5 Pr-NP1 followed by CH505 TF chTrimer boost with LNPs or 3M-052-AF + Alum was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• CH505 TF chTrimer Boost (CH505 TF chTrimer Boost)
• CH505M5 Pr-NP1 (CH505M5 Pr-NP1)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV | Phase 1 | Status: WITHDRAWN